TOUCHSTONE EXPLORATION (TXP) EPS Estimated At $-0.01; Ampio Pharmaceuticals Has 0.6 Sentiment

October 11, 2017 - By Marguerite Chambers

Analysts expect TOUCHSTONE EXPLORATION INC (TSE:TXP) to report $-0.01 EPS on November, 9.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.01 EPS. After having $-0.02 EPS previously, TOUCHSTONE EXPLORATION INC’s analysts see -50.00% EPS growth. It closed at $0.155 lastly. It is down 0.00% since October 11, 2016 and is . It has underperformed by 16.70% the S&P500.

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $55.95 million. The Firm is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. It currently has negative earnings. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Among 2 analysts covering Touchstone Exploration (TSE:TXP), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Touchstone Exploration had 5 analyst reports since August 14, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Monday, October 5 by Paradigm Research.

Knoll Capital Management Lp holds 1.79% of its portfolio in Ampio Pharmaceuticals Inc for 2.60 million shares. Noven Financial Group Inc. owns 245,667 shares or 0.08% of their US portfolio. Moreover, Element Capital Management Llc has 0.03% invested in the company for 290,312 shares. The Colorado-based Ghp Investment Advisors Inc. has invested 0.01% in the stock. Lmr Partners Llp, a United Kingdom-based fund reported 157,455 shares.

The stock increased 0.49% or $0.004 on October 10, reaching $0.82. About shares traded. Ampio Pharmaceuticals Inc (AMPE) has declined 79.44% since October 11, 2016 and is downtrending. It has underperformed by 96.14% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marguerite Chambers

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: